Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 486-494

  Bandyopadhyay, Sanghamitra ^a   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Brain iron homeostasis

Indexed keywords

8 QUINOLINOL; ACETYLCYSTEINE; ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AZITHROMYCIN; BETA SECRETASE; CLIOQUINOL; DEFEROXAMINE; DIMERCAPROL; ERYTHROMYCIN; FERRITIN; FERROPORTIN 1; FRAGILE X MENTAL RETARDATION PROTEIN; INTERLEUKIN 1; IRON CHELATING AGENT; IRON REGULATORY PROTEIN 1; JTR 009; MESSENGER RNA; PAROXETINE; PHENSERINE; PRESENILIN; SEMAGACESTAT; TETRATHIOMOLYBDIC ACID; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; AMYLOIDOSIS; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HOMEOSTASIS; HUMAN; INTERNAL RIBOSOME ENTRY SITE; IRON BALANCE; IRON HOMEOSTASIS; IRON METABOLISM; IRON OVERLOAD; IRON RESPONSIVE ELEMENT; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA SEQUENCE; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALZHEIMER'S DISEASE; AMYLOID PRECURSOR PROTEIN; BRAIN IRON HOMEOSTASIS;

5' UNTRANSLATED REGIONS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; HOMEOSTASIS; HUMANS; IRON; MICE; MICE, TRANSGENIC; PROTEIN BIOSYNTHESIS; RNA, MESSENGER;

EID: 84897954519     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.032     Document Type: Review

References (108)

1. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, and M. Ganguli et al. Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117 (Pubitemid 41797645)
2. S. Claeysen, M. Cochet, R. Donneger, A. Dumuis, J. Bockaert, and P. Giannoni Alzheimer culprits: cellular crossroads and interplay Cell Signalling 24 9 2012 1831 1840
3. C. Haass, C. Kaether, G. Thinakaran, and S. Sisodia Trafficking and proteolytic processing of APP Cold Spring Harbor Perspect Med 2 2012 a006270
4. H. Zhang, Q. Ma, Y.W. Zhang, and H. Xu Proteolytic processing of Alzheimer's beta-amyloid precursor protein J Neurochem 120 Suppl 1 2012 9 21
5. S. Bandyopadhyay, X. Huang, D.K. Lahiri, and J.T. Rogers Novel drug targets based on metallobiology of Alzheimer's disease Expert Opin Ther Targets 14 2010 1177 1197
6. S. Bandyopadhyay, L.E. Goldstein, D.K. Lahiri, and J.T. Rogers Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease Curr Med Chem 14 2007 2848 2864 (Pubitemid 350201652)
7. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, and A. Bayer et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223 (Pubitemid 351978111)
8. J.L. Grant, E.E. Ghosn, R.C. Axtell, K. Herges, H.F. Kuipers, and N.S. Woodling et al. Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis Sci Transl Med 4 2012 145ra05
9. R.S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, and S. Joffe et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med 369 2013 341 350
10. D. Lambracht-Washington, B.X. Qu, M. Fu, L.D. Anderson Jr., T.N. Eagar, and O. Stuve et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Abeta42 DNA vaccine for Alzheimer disease J Neuroimmunol 254 2013 63 68
11. J.A. Duce, A. Tsatsanis, M.A. Cater, S.A. James, E. Robb, and K. Wikhe et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease Cell 142 2010 857 867
12. H.H. Cho, C.M. Cahill, C.R. Vanderburg, C.R. Scherzer, B. Wang, and X. Huang et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1 J Biol Chem 285 2010 31217 31232
13. L. Zecca, M.B. Youdim, P. Riederer, J.R. Connor, and R.R. Crichton Iron, brain ageing and neurodegenerative disorders Nat Rev Neurosci 5 2004 863 873 (Pubitemid 39482155)
14. A.E. Oakley, J.F. Collingwood, J. Dobson, G. Love, H.R. Perrott, and J.A. Edwardson et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease Neurology 68 2007 1820 1825 (Pubitemid 46791395)
15. S. Fernaeus, K. Reis, K. Bedecs, and T. Land Increased susceptibility to oxidative stress in scrapie-infected neuroblastoma cells is associated with intracellular iron status Neurosci Lett 389 2005 133 136 (Pubitemid 41267213)
16. M.K. Olsen, S.L. Roberds, B.R. Ellerbrock, T.J. Fleck, D.K. McKinley, and M.E. Gurney Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord Ann Neurol 50 2001 730 740 (Pubitemid 33116132)
17. G.M. Bishop, S.R. Robinson, Q. Liu, G. Perry, C.S. Atwood, and M.A. Smith Iron: a pathological mediator of Alzheimer disease Dev Neurosci 24 2002 184 187 (Pubitemid 36151449)
18. S. Bandyopadhyay, C. Cahill, A. Balleidier, C. Huang, D.K. Lahiri, and X. Huang et al. Novel 5′ untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for Down syndrome and Alzheimer's disease PloS One 8 2013 e65978
19. J. Wang, and K. Pantopoulos Regulation of cellular iron metabolism Biochem J 434 2012 365 381
20. G. Balla, H.S. Jacob, J. Balla, M. Rosenberg, K. Nath, and F. Apple et al. Ferritin: a cytoprotective antioxidant strategem of endothelium J Biol Chem 267 1992 18148 18153
21. N. Komori, A. Kittel, D. Kang, D. Shackelford, E. Masliah, and J.A. Zivin et al. Reversible ischemia increases levels of Alzheimer amyloid protein precursor without increasing levels of mRNA in the rabbit spinal cord Brain Res Mol Brain Res 49 1997 103 112 (Pubitemid 27453120)
22. M. Fujioka, T. Taoka, Y. Matsuo, K. Mishima, K. Ogoshi, and Y. Kondo et al. Magnetic resonance imaging shows delayed ischemic striatal neurodegeneration Ann Neurol 54 2003 732 747 (Pubitemid 37498957)
23. J.M. Roch, E. Masliah, A.C. Roch-Levecq, M.P. Sundsmo, D.A. Otero, and I. Veinbergs et al. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor PNAS 91 1994 7450 7454 (Pubitemid 24238201)
24. S. Bandyopadhyay, D.M. Hartley, C.M. Cahill, D.K. Lahiri, N. Chattopadhyay, and J.T. Rogers Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase J Neurosci Res 84 2006 106 118 (Pubitemid 44023067)
25. H.G. Lee, R.J. Castellani, X. Zhu, G. Perry, and M.A. Smith Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective Int J Exp Pathol 86 2005 133 138 (Pubitemid 40813909)
26. R.J. Castellani, H.G. Lee, S.L. Siedlak, A. Nunomura, T. Hayashi, and M. Nakamura et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta J Alzheimers Dis 18 2009 447 452
27. K. Honarmand Ebrahimi, C. Dienemann, S. Hoefgen, M.E. Than, P.L. Hagedoorn, and W.R. Hagen The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain PLoS One 8 2013 e72177
28. S. Oshiro, M.S. Morioka, and M. Kikuchi Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis Adv Pharmacol Sci 2011 2011 378278
29. M. Asai, C. Hattori, B. Szabo, N. Sasagawa, K. Maruyama, and S. Tanuma et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase Biochem Biophys Res Commun 301 2003 231 235 (Pubitemid 36268873)
30. S. Musardo, E. Marcello, F. Gardoni, and M. Di Luca ADAM10 in synaptic physiology and pathology Neurodegener Dis 2013
31. E. Marcello, C. Saraceno, S. Musardo, H. Vara, A.G. de la Fuente, and S. Pelucchi et al. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease J Clin Invest 123 2013 2523 2538
32. R. Epis, E. Marcello, F. Gardoni, C. Vastagh, M. Malinverno, and C. Balducci et al. Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease Brain 133 2010 3323 3335 A journal of neurology
33. K. Endres, and F. Fahrenholz The Role of the anti-amyloidogenic secretase ADAM10 in shedding the APP-like proteins Curr Alzheimer Res 9 2012 157 164
34. A. Schroeder, F. Fahrenholz, and U. Schmitt Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease J Alzheimers Dis 16 2009 309 314
35. S.H. Zaidi, and J.S. Malter Amyloid precursor protein mRNA stability is controlled by a 29-base element in the 3′-untranslated region J Biol Chem 269 1994 24007 24013
36. C.J. Westmark, and J.S. Malter FMRP mediates mGluR5-dependent translation of amyloid precursor protein PLoS Biol 5 2007 e52
37. T. Zu, B. Gibbens, N.S. Doty, M. Gomes-Pereira, A. Huguet, and M.D. Stone et al. Non-ATG-initiated translation directed by microsatellite expansions PNAS 108 2011 260 265
38. K. Mori, S.M. Weng, T. Arzberger, S. May, K. Rentzsch, and E. Kremmer et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS Science 339 2013 1335 1338
39. J. Rogers Medicinal inorganic chemistry symposium series J.L. Sessler, S.R. Doctrow, T.J. McMurry, S.J. Lippard, Amyloid Precursor Protein and Ferritin Translation: Implications for Metals and Alzheimer's Disease Therapeutics J. Am. Chem. Soc. 903 2005 215 251 (Chapter 13)
40. J.T. Rogers, J.D. Randall, C.M. Cahill, P.S. Eder, X. Huang, and H. Gunshin et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript J Biol Chem 277 2002 45518 45528 (Pubitemid 36159162)
41. S. Bandyopadhyay, X. Huang, H. Cho, N.H. Greig, M.B. Youdim, and J.T. Rogers Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5′ untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator J Neural Transm Suppl 2006 237 247 (Pubitemid 351412125)
42. E.S. Athan, J.H. Lee, A. Arriaga, R.P. Mayeux, and B. Tycko Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease Arch Neurol 59 2002 1793 1799 (Pubitemid 35340491)
43. A. Venti, T. Giordano, P. Eder, D.K. Lahiri, N.H. Greig, and J.T. Rogers The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region Ann NY Acad Sci 1035 2004 34 48 (Pubitemid 40362325)
44. A.L. Friedlich, R.E. Tanzi, and J.T. Rogers The 5′-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element Mol Psychiatry 12 2007 222 223 (Pubitemid 46328508)
45. D. Olivares, X. Huang, L. Branden, N.H. Greig, and J.T. Rogers Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element Int J Mol Sci 10 2009 1226 1260
46. C.M. Cahill, D.K. Lahiri, X. Huang, and J.T. Rogers Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases Biochim Biophys Acta 1790 2009 615 628
47. M.M. Qureshi, R.H. Brown, J.T. Rogers, and M. Cudkowicz Serum ferritin and metal levels as risk factors for ALS Open Neurol J 2 2008 51 54
48. J.T. Rogers, and D.K. Lahiri Metal and inflammatory targets for Alzheimer's disease Curr Drug Targets 5 2004 535 551 (Pubitemid 39004428)
49. A.M. Thomson, J.T. Rogers, and P.J. Leedman Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation Int J Biochem Cell Biol 31 1999 1139 1152 (Pubitemid 29454550)
50. P. Piccinelli, and T. Samuelsson Evolution of the iron-responsive element RNA 13 2007 952 966 (Pubitemid 46984887)
51. W. Wang, X. Di, R.B. D'Agostino Jr., S.V. Torti, and F.M. Torti Excess capacity of the iron regulatory protein system J Biol Chem 282 2007 24650 24659 (Pubitemid 47347505)
52. T. LaVaute, S. Smith, S. Cooperman, K. Iwai, W. Land, and E. Meyron-Holtz et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice Nat Genet 27 2001 209 214 (Pubitemid 32157451)
53. S.A. Anderson, C.P. Nizzi, Y.I. Chang, K.M. Deck, P.J. Schmidt, and B. Galy et al. The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption Cell Metab 17 2013 282 290
54. J.R. Burdo, D.A. Antonetti, E.B. Wolpert, and J.R. Connor Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system Neuroscience 121 2003 883 890 (Pubitemid 37324587)
55. L.J. Wu, A.G. Leenders, S. Cooperman, E. Meyron-Holtz, S. Smith, and W. Land et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier Brain Res 1001 2004 108 117 (Pubitemid 38221533)
56. A.A. Raha, R.A. Vaishnav, R.P. Friedland, A. Bomford, and R. Raha-Chowdhury The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease Acta Neuropathol Commun. 1 1 2013 Sep 3 55 10.1186/2051-5960-1-55
57. H. Gunshin, C.R. Allerson, M. Polycarpou-Schwarz, A. Rofts, J.T. Rogers, and F. Kishi et al. Iron-dependent regulation of the divalent metal ion transporter FEBS Lett 509 2001 309 316 (Pubitemid 34015962)
58. A.T. McKie, P. Marciani, A. Rolfs, K. Brennan, K. Wehr, and D. Barrow et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation Mol Cell 5 2000 299 309 (Pubitemid 30628088)
59. N. Song, J. Wang, H. Jiang, and J. Xie Ferroportin1 and hephaestin overexpression attenuate iron-induced oxidative stress in MES23.5 dopaminergic cells J Cell Biochem 110 2014 1063 1072
60. A.M. Thomson, C.M. Cahill, H.H. Cho, K.D. Kassachau, M.R. Epis, and K.R. Bridges et al. The acute box cis-element in human heavy ferritin mRNA 5′-untranslated region is a unique translation enhancer that binds poly(C)-binding proteins J Biol Chem 280 2005 30032 30045 (Pubitemid 41216179)
61. J.T. Rogers, L.M. Leiter, J. McPhee, C.M. Cahill, S.S. Zhan, and H. Potter et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences J Biol Chem 274 1999 6421 6431 (Pubitemid 29111057)
62. A. Rovelet-Lecrux, T. Frebourg, H. Tuominen, K. Majamaa, D. Campion, and A.M. Remes APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage J Neurol Neurosurg Psychiatry 78 10 2007 1158 1159
63. L. Guyant-Marechal, A. Rovelet-Lecrux, L. Goumidi, E. Cousin, D. Hannequin, and G. Raux et al. Variations in the APP gene promoter region and risk of Alzheimer disease Neurology 68 2007 684 687 (Pubitemid 46667816)
64. A. Rovelet-Lecrux, D. Hannequin, G. Raux, N.L. Meur, A. Laquerriere, and A. Vital et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat Genet 38 2006 24 26 (Pubitemid 43011878)
65. S.I. Borysov, A. Granic, J. Padmanabhan, C.E. Walczak, and H. Potter Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule motors Cell Cycle 10 2013 1397 1410
66. A. Granic, J. Padmanabhan, M. Norden, and H. Potter Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP Mol Biol Cell 21 2012 511 520
67. D.I. Boeras, A. Granic, J. Padmanabhan, N.C. Crespo, A.M. Rojiani, and H. Potter Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy Neurobiol Aging 29 2008 319 328 (Pubitemid 351215587)
68. J. Theuns, N. Brouwers, S. Engelborghs, K. Sleegers, V. Bogaerts, and E. Corsmit et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease Am J Hum Genet 78 2006 936 946 (Pubitemid 43787686)
69. D.K. Lahiri, B. Maloney, J.T. Rogers, and Y.W. Ge PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-beta precursor protein via a tissue-specific proximal regulatory element (PRE) BMC Genomics 14 2013 68
70. R. Vassar, B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, and P. Denis et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 286 1999 735 741 see comments
71. R. Vassar, D.M. Kovacs, R. Yan, and P.C. Wong The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential J Neurosci 29 2009 12787 12794
72. A. Salehi, J.D. Delcroix, P.V. Belichenko, K. Zhan, C. Wu, and J.S. Valletta et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration Neuron 51 2006 29 42 (Pubitemid 43963336)
73. A. Salehi, M. Faizi, D. Colas, J. Valletta, J. Laguna, and R. Takimoto-Kimura et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome Sci Transl Med 1 2009 7ra17
74. J.T. Rogers, A.I. Bush, H.H. Cho, D.H. Smith, A.M. Thomson, and A.L. Friedlich et al. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease Biochem Soc Trans 36 2009 1282 1287
75. A. Salehi, M. Faizi, D. Colas, J. Valletta, J. Laguna, and R. Takimoto-Kimura et al. Restoration of norepinephrine-modulated contextrual memory in a mouse model of down syndrome Sci Transl Med 1 2009 1 9
76. N.P. Belichenko, P.V. Belichenko, A.M. Kleschevnikov, A. Salehi, R.H. Reeves, and W.C. Mobley The Down syndrome critical region is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome J Neurosci 29 2009 5938 5948
77. J.T. Rogers, J.D. Randall, P.S. Eder, X. Huang, A.I. Bush, and R.E. Tanzi et al. Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region J Mol Neurosci 19 2002 77 82 (Pubitemid 35013337)
78. C.W. Ritchie, A.I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, and L. MacGregor et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch Neurol 60 2003 1685 1691 (Pubitemid 37521621)
79. Y.H. Zhang, J. Raymick, S. Sarkar, D.K. Lahiri, B. Ray, and D. Holtzman et al. Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease Curr Alzheimer Res 10 2013 494 506
80. N.G. Faux, C.W. Ritchie, A. Gunn, A. Rembach, A. Tsatsanis, and J. Bedo et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses J Alzheimers Dis 20 2010 509 516
81. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 2008 779 786
82. P.A. Adlard, A. Sedjahtera, L. Gunawan, L. Bray, D. Hare, and J. Lear et al. A novel approach to rapidly prevent age-related cognitive decline Aging Cell 28 2013 10.1111/acel.12178
83. P.A. Adlard, L. Bica, A.R. White, M. Nurjono, G. Filiz, and P.J. Crouch et al. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease PloS One 6 2011 e17669
84. V. Medici, and G.C. Sturniolo Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications IDrugs 11 2008 592 606 Invest Drugs J
85. S. Tucker, M. Ahl, H.H. Cho, S. Bandyopadhyay, G.D. Cuny, and A.I. Bush et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine Curr Alzheimer Res 3 2006 221 227 (Pubitemid 43988135)
86. D.K. Lahiri, D. Chen, B. Maloney, H.W. Holloway, Q.S. Yu, and T. Utsuki et al. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice J Pharmacol Exp Ther 320 2007 386 396 (Pubitemid 46025753)
87. K.T. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, and A. Brossi et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development PNAS 98 2001 7605 7610 (Pubitemid 32567995)
88. L.J. Morse, S.M. Payton, G.D. Cuny, and J.T. Rogers FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein J Mol Neurosci 24 2004 129 136 (Pubitemid 41359178)
89. H.H. Cho, C.M. Cahill, C. Vanderburg, C.R. Scherzer, B. Wang, and C. Huang et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1 J Biol Chem 285 41 2010 31217 31232
90. S. Bandyopadhyay, J. Ni, A. Ruggiero, K. Walshe, M.S. Rogers, and N. Chattopadhyay et al. A high-throughput drug screen targeted to the 5′ untranslated region of Alzheimer amyloid precursor protein mRNA J Biomol Screen 11 2006 469 480 (Pubitemid 44222998)
91. D.R. Crapper McLachlan, A.J. Dalton, T.P. Kruck, M.Y. Bell, W.L. Smith, and W. Kalow et al. Intramuscular desferrioxamine in patients with Alzheimer's disease Lancet 337 1991 1304 1308
92. J.T. Rogers, J.D. Randall, C.M. Cahill, P.S. Eder, X. Huang, and H. Gunshin et al. An iron-responsive element type II in the 5′ untranslated region of the Alzheimer's amyloid precursor protein transcript J Biol Chem 277 2002 45518 45528 (Pubitemid 36159162)
93. S. Payton, C.M. Cahill, J.D. Randall, S.R. Gullans, and J.T. Rogers Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol J Mol Neurosci 20 2003 267 275 (Pubitemid 38146981)
94. M.L. Maccecchini, M.Y. Chang, C. Pan, V. John, H. Zetterberg, and N.H. Greig Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans J Neurol Neurosurg Psychiatry 83 2013 894 902
95. N.T. Ross, S.R. Metkar, H. Le, J. Burbank, C. Cahill, A. Germain, L. MacPherson, J. Bittker, M. Palmer, J. Rogers, and S.L. Schreiber Probe Reports from the NIH Molecular Libraries Program [Internet] 2010-2011 National Center for Biotechnology Information (US) Bethesda (MD) PMID 21634082
96. A. Singh, S. Haldar, K. Horback, C. Tom, L. Zhou, and H. Meyerson et al. Prion protein regulates iron transport by functioning as a ferrireductase J Alzheimers Dis 35 2013 541 552
97. R.C. Mohs A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced Alzheimers Dementia 4 2008 S85 S87
98. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nat Med 9 4 2003 448 452 (Pubitemid 36460079)
99. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement;8:261-71.
100. A. Mullard Sting of Alzheimer's failures offset by upcoming prevention trials Nat Rev Drug Discovery 11 2012 657 660
101. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J Neurochem 110 2009 1129 1134
102. J.A. Bartlett, J. Johnson, G. Herrera, N. Sosa, A. Rodriguez, and Q. Liao et al. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine JAIDS, J Acquired Immune Defic Syndr 43 2006 284 292 (Pubitemid 44674008)
103. J.A. Bartlett Lack of protease inhibitor resistance following treatment failure - too good to be true J Clin Invest 123 2013 3704 3705
104. H. Zheng, M. Jiang, M.E. Trumbauer, D.J. Sirinathsinghji, R. Hopkins, and D.W. Smith et al. beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity Cell 81 1995 525 531
105. A.R. White, R. Reyes, J.F. Mercer, J. Camakaris, H. Zheng, and A.I. Bush et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice Brain Res 842 1999 439 444 (Pubitemid 29475178)
106. S. Mikkilineni, I. Cantuti-Castelvetri, C.M. Cahill, A. Balliedier, N.H. Greig, and J.T. Rogers The anticholinesterase phenserine and its enantiomer posiphen as 5′ untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression Parkinson's Dis 2012 2012 142372
107. J.T. Rogers, S. Mikkilineni, I. Cantuti-Castelvetri, D.H. Smith, X. Huang, and S. Bandyopadhyay et al. The alpha-synuclein 5′ untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen J Neural Transm 118 2011 493 507
108. L. Mandinov, A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, and V. Kolev et al. Copper chelation represses the vascular response to injury PNAS 100 2003 6700 6705 (Pubitemid 36666643)